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Background: ASC mediates apoptosis and 
necrosis of tumor cells and necrosis of 
microbe-infected macrophages. 
Result: ASC mediates necrosis only when cells 
express caspase-1; however, inhibition of 
caspase-1 proteolytic activity did not suppress 
the necrosis. 
Conclusion: Caspase-1 but not is proteolytic 
activity is essential for ASC-mediated necrosis. 
Significance: This paper explains why ASC 




The adaptor protein, apoptosis-associated 
speck-like protein containing a 
caspase-recruitment domain (ASC) connects 
pathogen/danger sensors such as NLRP3 and 
NLRC4 with caspases, and is involved in 
inflammation and cell death. We have found 
that ASC activation induced caspase-8- 
dependent apoptosis or CA-074Me (cathepsin 
B inhibitor)-inhibitable necrosis depending 
on the cell type. Unlike necroptosis, another 
necrotic cell death, ASC-mediated necrosis 
was neither RIP3-dependent nor 
necrostatin-1- inhibitable. Although 
Ac-YVAD-CMK (caspase-1 inhibitor) did not 
inhibit ASC-mediated necrosis, 
comprehensive gene-expression analyses 
indicated that caspase-1 expression coincided 
with the necrosis-type. Furthermore, 
caspase-1 knockdown converted 
necrosis-type cells to apoptosis-type, while 
exogenous expression of either wild-type or 
catalytically inactive caspase-1 did the 
opposite. Knockdown of caspase-1, but not 
Ac-YVAD-CMK, suppressed the monocyte 
necrosis induced by Staphylococcus and 
Pseudomonas infection. Thus, the catalytic 
activity of caspase-1 is dispensable for 
necrosis induction. Intriguingly, a short 
period of caspase-1 knockdown inhibited 
IL-1β production but not necrosis, although 
longer knockdown suppressed both responses. 
Possible explanations of this phenomenon are 
discussed. 
 
ASC is an adaptor protein that connects 
several pattern recognition receptors (e.g., 
NLRP3, NLRC4) with caspase-1 (1,2). These 
pattern recognition receptors directly or 
indirectly recognize microbial molecular 
patterns (e.g. microbial RNA, flagellin) and/or 
danger signals from injured cells (e.g. ATP, uric 
acid), and then, together with ASC, they serve 
as platforms for the proteolytic maturation of 
caspase-1, which in turn catalyzes the 
proteolytic maturation of proinflammatory 
cytokines such as IL-1β and IL-18. Accordingly, 
ASC-deficient macrophages are severely 
defective in secreting these cytokines in 
response to microbial infection (3-5). 
Gain-of-function NLRP3 mutations cause 
auto-inflammatory syndromes, now collectively 
called cryopyrin-associated periodic syndromes 
(CAPS) (6). Importantly, IL-1 receptor 
antagonist has been shown to be effective in 
treating these syndromes. Thus, much attention 
has been paid to the role of ASC in 
caspase-1-mediated IL-1β maturation.  
ASC also plays an important role in the 
monocyte and macrophage cell death induced 
by microbial infection. For instance, infection 
by an intracellular bacterium such as Salmonella 
typhimurium, Pseudomonas (P.) aeruginosa, or 
Listeria monocytogenes induces caspase-1- 
mediated cell death called “pyroptosis” (7-9). It 
has been described that pyroptosis has 
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characteristics of both necrosis (e.g. cell 
swelling and plasma membrane rupture) and 
apoptosis (nuclear shrinkage) (10). As expected 
from the fact that ASC plays an important role 
in caspase-1 activation, recent studies have 
demonstrated that ASC also plays an important 
role in pyroptosis (11,12). More recently, it was 
demonstrated that the expression of CAPS- 
associated NLRP3 mutants or the activation of 
endogenous NLRP3 by Shigella flexneri 
infection induces necrotic cell death in the 
THP-1 human monocytic cell line and/or mouse 
macrophages (13,14). This necrotic cell death is 
also mediated by ASC; however, it is inhibited 
by a cathepsin B inhibitor, CA-074Me but not 
by a caspase-1 inhibitor. Thus, this type of 
necrotic cell death has been considered to be 
distinct from pyroptosis, and it was named 
“pyronecrosis” (14).  
Another line of studies demonstrated that 
ASC has the potential to induce apoptosis. ASC 
was originally identified as a protein that forms 
large aggregates in apoptotic human leukemia 
cells treated with chemotherapeutic agents (15), 
and as the product of a gene that is silenced in 
human cancer tissues by DNA methylation (16). 
In addition, it was demonstrated that ASC 
expression is induced by the p53 tumor 
suppressor, and is involved in etoposide- 
induced apoptosis (17). Thus, ASC-mediated 
apoptosis seems to be important for tumor 
suppression and for cancer cell chemosensitivity. 
Furthermore, we recently demonstrated that 
transplanted human tumors in nude mice were 
completely eradicated by ASC activation in the 
tumor cells (18). Thus, ASC is a promising 
molecular target for cancer therapy. We 
previously showed that oligomerization of ASC 
using an NLRC4-mimicry system induced 
caspase-8-mediated apoptosis in five human 
cancer cell lines, including the NUGC-4 gastric 
cancer cell line (19). More recently, we found 
that ASC activation using the NLRC4-mimicry 
system or a CAPS-associated mutant of NLRP3 
induced necrotic cell death in the COLO205 
human colon adenocarcinoma cell line (18).  
In this study, we investigated the mode of 
cell death induced by NLRC4-mimicry in six 
other ASC-expressing tumor cell lines, and 
found that they were separated into apoptosis- 
and necrosis-type. We next sought to identify 
the molecular determinant of the mode of 
ASC-mediated cell death. We found that ASC 
activation induced necrosis in cells expressing 
caspase-1, but it induced caspase-8-dependent 
apoptosis in cells lacking caspase-1. Intriguingly, 
caspase-1, but not its catalytic activity, was 
essential for the ASC-mediated necrosis. The 
same was true for the ASC-dependent necrosis 
of the NOMO-1 human monocytic cell line 




Reagents- An anti-human ASC mAb was 
prepared as described previously (20). 
Anti-caspase-1 polyclonal antibody (Cell 
Signaling, Beverly, MA), anti-cleaved 
caspase-1 mAb (clone D57A2, Cell Signaling), 
anti-β-actin mAb (clone AC-15, Sigma), anti- 
GAPDH mAb (clone MAB374, Millipore, 
Billerica, MA), MDP (Sigma, Saint Louis, MO), 
Z-IETD-FMK (R&D Systems, Minneapolis, 
MN), Ac-YVAD-CMK (Bachem, Torrance, 
CA), Z-DEVD-FMK, and CA-074Me (Merck 
Japan, Tokyo, Japan) were purchased. 
 
Plasmids- The expression plasmids for 
Flag-C12N2, caspase-1, the caspase-1-C285S 
mutant, and pro-IL-1β were described 
previously (19,21-23). Lentiviral vectors 
expressing NLRP3 and NLRP3-Y570C were 
described previously (18). To generate lentiviral 
vectors expressing GFP, Flag-C12N2, caspase-1, 
and the caspase-1-C285S mutant, these cDNAs 
were inserted into pLenti6/V5-DEST 
(Invitrogen, Carlsbad, CA). To generate a 
plasmid expressing the GFP-Caspase-1 fusion 
protein (pEGFP-Casp1), the caspase-1 cDNA 
was cloned into a pEGFP-C1 vector (BD 
Clontech, Mountain View, CA). To generate 
lentiviral vectors expressing control and 
caspsae-1-targeting shRNA, oligo DNAs, 





were cloned into the pLKO.1 TRC vector 
(Addgene, Cambridge, MA). 
 
Human cell lines- The NUC12N2 and 
CLC12N2 cell lines were described previously 
(18,19). The NUGC-4, COLO205, KLM-1 and 
MIAPaca2 cell lines were obtained from the 
Cell Resource Center for Biomedical Research, 
Tohoku University (Sendai, Miyagi, Japan). The 
C32TG, G-361, HMV-II, SK-MEL-28, and 
KU812 cell lines were obtained from the 
RIKEN BioResource Center (Ibaraki, Tsukuba, 
3 
Japan). The NOMO-1 cell line was obtained 
from the Health Science Research Resources 
Bank (Osaka, Japan). The THP-1 cell line was 
obtained from the American Type Culture 
Collection (Manassas, VA). To generate 
NOMO1-shCont and NOMO1-shCasp1 stable 
cell lines, NOMO-1 cells were transduced with 
a pLKO.1 lentiviral vector expressing control 
shRNA or caspase-1-targeting shRNA. The 
transduced cells were selected under puromycin 
treatment. The NU-GFP-Casp1 cell line was 
generated as follows: NUC12N2 cells were 
transfected with pEGFP-Casp1 using the Neon 
Transfection System (Invitrogen), and 
GFP-expressing cells were sorted by flow 
cytometry. To generate the NU-Casp1WT and 
NU-Casp1C285S cell lines, NUC12N2 cells 
were transduced with pLenti6/V5-DEST 
expressing the wild-type or C285S mutant of 
caspase-1. To generate the SKC12N2 cell line, 
SK-Mel-28 cells were transduced with 
pLenti6/V5-DEST expressing Flag-C12N2. The 
transduced cells were selected by blasticidin. 
 
Apoptosis and necrosis assay- The mode of 
cell death (apoptosis or necrosis) was 
determined primarily by the morphology of the 
dying cells. The proportions of apoptotic and 
necrotic cells were determined by flow 
cytometry after staining with propidium iodide 
(PI) and Cy5-annexin V as described previously 
(18). PI(+)Cy5(-) cells and PI(-)Cy5(+) cells 
were considered necrotic and early apoptotic 
cells, respectively. PI(+)Cy5(+) cells were 
considered necrotic when increased PI staining 
preceded or occurred simultaneously with 
increased Cy5-Annexin V staining, whereas 
increased Cy5-Annexin V staining that 
preceded PI staining was considered to be an 
indication of the secondary necrosis of apoptotic 
cells. Otherwise, the proportions of apoptotic 
and necrotic cells were determined in situ after 
Hoechst33342 and PI staining, as described 
previously (18). A cell with a pyknotic nucleus 
without PI staining was considered apoptotic, 
while a PI(+) cell without profound nuclear 
condensation was considered necrotic. In some 
experiments, the proportion of necrosis was 
assessed by the release of cytoplasmic LDH into 
culture supernatants using the Cytotox 96 kit 
(Promega), according to the manufacturer’s 
protocol. In some experiments, cell death was 
assessed by WST1 assay, as described 
previously (24). 
 
Microarray analysis- Microarray analyses 
were performed using the Whole Human 
Genome Microarray Kit (G4100F, Agilent, 
Santa Clara, CA), according to the 
manufacturer’s protocol. Total RNA was 
purified from CLC12N2 subclones 
(CLC12N2-Nec, CLC12N2-Apo) or from 
COLO205 and NUGC-4 cells using the RNeasy 
plus kit (Qiagen, Hilden, Germany). Cy3- and 
Cy5-labeled cRNAs were prepared using the 
Agilent Quick Amp Labeling Kit, Two-color 
(Agilent). Hybridization and analysis were 
performed as descried previously (25). 
 
RT-PCR and real-time RCR- Total RNA was 
purified using TRIZOL reagent (Invitrogen), 
and cDNA was synthesized using the 
PrimeScript RT reagent Kit (Takara Bio, Shiga, 















Real-time PCR was performed using the 
THUNDERBIRD SYBR qPCR Mix (Toyobo, 
Osaka, Japan). The following primer sequences 
obtained from PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/) were 







Transfection of genes and siRNAs- Viral 
transduction was performed as described 
previously (18). CLC12N2 or NOMO-1 cells 
were transfected with siRNA (20 nM) using the 
Neon Transfection System. The ASC-targeting 
(HSS147064), NLRP3-targeting (HSS132811), 
and NLRC4-targeting (HSS126850) siRNAs 
were purchased from Invitrogen. The 
caspase-1-targeting siRNA (L-004401-00) was 
purchased from Dharmacon (Chicago, IL). 
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Measurement of IL-1β- The amount of 
human IL-1β in culture supernatants was 
determined using the OptEIA ELISA Kit (BD 
Pharmingen, San Diego, CA), according to the 
manufacturer’s protocol. 
 
Bacterial infection- Staphylococcus (S.) 
aureus (strain Smith, kindly provided by Dr. 
Nakanishi, Kanazawa University, Kanazawa, 
Ishikawa, Japan) and P. aeruginosa (JCM14847, 
Riken Bioresource Center, Wako, Saitama, 
Japan) in the log phase were used for infection. 
NOMO-1 and THP-1 cells were infected with 
these bacteria in antibiotic-free medium in 
96-well plates. The plates were briefly 
centrifuged to improve the interaction between 
cells and bacteria. One hour after the infection, 





ASC activation induces apoptosis or necrosis 
in tumor cells derived from various tissues. To 
investigate ASC’s functions, we previously 
established an experimental system in which a 
chimeric protein (C12N2) consisting of the 
caspase-recruitment domain from NLRC4, 
and the nucleotide-binding oligomerization 
domain and leucine-rich repeats from NOD2 
(also called NLRC2), a sensor for muramyl 
dipeptide (MDP), was expressed in cells (20). In 
this system, the simple addition of MDP to the 
culture medium induces ASC-dependent 
responses in the cells. Hereafter, this system is 
termed NLRC4-mimicry. Using this system, we 
previously showed that ASC activation induces 
apoptosis in the NUGC-4 human stomach 
cancer cell line, but induced necrosis in the 
COLO205 human colon adenocarcinoma cell 
line (18). In the present study, we further 
investigated whether ASC activation induces 
apoptosis or necrosis in other ten tumor cell 
lines, including leukemia cell lines, melanomas, 
and pancreatic cancers. Among them, six 
expressed substantial amounts of ASC (Fig. 1A). 
These ten lines were transfected with C12N2 
and treated with MDP. Among the six ASC- 
expressing lines, four (two monocytic leukemia 
cell lines, one melanoma, and one pancreatic 
cancer) exhibited necrosis, while two 
(melanomas) showed apoptosis (Fig. 1B-E, and 
see supplemental Fig. S1). MDP treatment 
without C12N2 transfection induced neither 
necrosis nor apoptosis in these cell lines (data 
not shown). Consistent with our previous 
findings (18,19), the NLRC4-mimicry-induced 
cell death of both apoptosis-type and 
necrosis-type cells was inhibited by ASC 
knockdown using siRNA (data not shown). The 
remaining cell lines, which expressed little or no 
ASC, were resistant to this procedure, 
confirming that the cell death induced by this 
procedure is ASC-dependent. These results 
indicate that ASC activation induces apoptosis 
or necrosis in ASC-expressing tumor cells of 
various tissue origins. 
 
Effect of protease inhibitors on 
ASC-mediated cell death. We previously 
demonstrated that the ASC-mediated apoptosis 
of NUGC-4 cells was inhibited by a caspase-8 
inhibitor, Z-IETD-FMK, while the 
ASC-mediated necrosis in COLO205 cells was 
inhibited by a cathepsin B inhibitor, CA-074Me 
(18). In addition, ASC has been implicated in 
pyroptosis that is inhibited by a caspase-1 
inhibitor. Therefore, to further classify the type 
of cell death, we investigated the effect of these 
protease inhibitors. Consistent with our previous 
results, ASC-mediated cell death of all the 
apoptosis-type was inhibited by Z-IETD-FMK 
but not by CA-074Me (Fig. 2A). In contrast, the 
ASC-mediated cell death of necrosis-type cells 
was inhibited by CA-074Me, whereas neither 
Ac-YVAD-CMK nor Z-IETD-FMK inhibited it 
(Fig. 2B). These characteristics of 
ASC-mediated necrosis are shared with 
pyronecrosis.  
 
The RIP1-RIP3 axis is not involved in the 
ASC-mediated necrosis. Death receptors that 
normally induce caspase-8-mediated apoptosis 
can elicit necrotic cell death (necroptosis), 
especially when caspases are inhibited. 
Necroptosis requires the expression of RIP1 and 
RIP3 (26-29), and is inhibited by a RIP1 
inhibitor, necrostatin-1 (30). To investigate 
RIP3’s involvement in ASC-mediated necrosis, 
we examined the RIP3 expression in tumor cell 
lines. RIP3 expression coincides with neither 
necrosis- nor apoptosis-type cells (Fig. 3A). In 
addition, necrostatin-1 did not inhibit the 
NLRC4-mimicry-induced necrosis in THP-1 
cells, whereas it inhibited the necroptosis 
induced by TNF-α plus Z-VAD-FMK 
(pan-caspase inhibitor) in the same cell line (Fig. 
3B). These results indicate that ASC-mediated 
necrosis is distinct from necroptosis. 
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Caspase-1 expression correlates with the 
necrotic phenotype. The stable transfectants of 
COLO205 cells expressing C12N2 (CLC12N2) 
exhibit necrosis in response to MDP stimulation 
(18). By limiting dilution, we obtained one 
subclone of CLC12N2 cells that exhibited 
necrosis (CLC12N2-Nec) just like the parental 
CLC12N2 cells and another subclone that 
exhibited apoptosis (CLC12N2-Apo) upon ASC 
activation (Fig. 4A and see supplemental Movie 
S1 and Movie S2). Consistent with our previous 
conclusion that ASC-mediated apoptosis is 
caspase-8- dependent (19), Z-IETD-FMK 
inhibited the cell death of CLC12N2-Apo but 
not CLC12N2-Nec cells (Fig. 4B).  
To identify what determines the mode of 
ASC-mediated cell death, we compared the 
gene expression profiles between 
CLC12N2-Nec and CLC12N2-Apo cells and 
between the original COLO205 (necrosis-type) 
and NUGC-4 cells (apoptosis-type). We first 
selected those genes that expressed either more 
or less consistently in CLC12N2-Nec compared 
to CLC12-Apo cells and in COLO205 cells 
compared to NUGC-4 cells. Among them, the 
top 10 genes with the greatest difference in 
expression between the CLC12N2-Nec and 
CLC12-Apo cells are shown in Fig. 4C. Using 
real-time PCR, we examined the expression of 
these 20 genes in other tumor cell lines. To our 
surprise, CASP1 was the only gene that 
completely coincided with the necrosis-type cell 
lines (Fig. 4D and see supplemental Fig. S2). 
Although CARD16 expression had a weak 
correlation with the necrosis-type, CARD16 
knockdown did not inhibit the MDP-induced 
necrosis of CLC12N2-Nec cells (see 
supplemental Fig. S3), suggesting that CARD16 
is not required for ASC-mediated necrosis. No 
gene completely coincided with the apoptotic 
phenotype (see supplemental Fig. S4). Western 
blot analyses confirmed that substantial 
amounts of caspase-1 protein were expressed in 
the necrosis-type but not apoptosis-type cell 
lines (Fig. 4E). We previously reported that 
NLRC4-mimicry induces apoptosis in four 
gastrointestinal cancer cell lines, including 
NUGC-4, and one lung cancer cell line (19). 
Consistent with the above results, all of these 
cell lines expressed no caspase-1 (see 
supplemental Fig. S5). Therefore, caspase-1 is a 
novel cellular factor determining the mode of 
cell death. 
 
Caspase-1 is required for ASC-mediated 
necrosis. To investigate whether caspase-1 is 
required for ASC-mediated necrosis, caspase-1 
expression in CLC12N2-Nec cells was 
down-regulated using siRNA. Although the 
one-time transfection of caspase-1-targeting 
siRNA but not control siRNA severely reduced 
the expression of caspase-1 protein, the 
NLRC4-mimicry-induced necrosis was only 
slightly suppressed by the caspase-1-targeting 
siRNA (Fig. 5A). However, after a 6- or 9-day 
culture with repetitive siRNA transfection, the 
necrosis was reduced and, interestingly, 
apoptosis gradually increased. These results 
suggest that a special caspase-1 with a long 
half-life is involved in ASC-mediated necrosis. 
To confirm the role of caspase-1 in 
ASC-mediated necrosis, we introduced a 
GFP-caspase-1 fusion gene into NUC12N2 cells 
(C12N2-expressing NUGC-4 cells), and thereby 
established NU-GFP-Casp1 cells. MDP 
stimulation induced apoptosis in NUC12N2 
cells, but induced necrosis in NU-GFP-Casp1 
cells (Fig. 5B). Thus, exogenous caspase-1 
expression converted apoptosis-type cells to 
necrosis-type. 
CAPS-associated NLRP3 mutants induce 
necrotic cell death in the human monocytic 
leukemia cell line THP-1 (13,14). Here we 
found that one such mutant, NLRP3-Y570C, but 
not the wild-type NLRP3, induced necrosis in 
another human monocytic cell line, NOMO-1. 
Consistent with the NLRC4-mimicry-induced 
necrosis of CLC12N2 cells, the NLRP3-Y570C 
-induced necrosis was suppressed by ASC- 
targeting siRNA (Fig. 5C) and stable expression 
of caspase-1-targeting shRNA (Fig. 5D), whose 
target sequence was completely different from 
that of the caspase-1-targeting siRNA used 
above. Furthermore, the NLRP3-Y570C- 
induced necrosis was converted to apoptosis by 
suppressing caspase-1 expression (Fig. 5E, F). 
Z-IETD-FMK inhibited the apoptosis observed 
in caspase-1-deficient cells, but not the necrosis 
observed in the caspase-1-sufficient cells (Fig. 
5F), indicating that ASC activation induces 
caspase-8-dependent apoptosis in cells lacking 
caspase-1.  
 
Caspase-1 catalytic activity is not required 
for ASC-mediated necrosis. Because 
Ac-YVAD-CMK did not inhibit the 
NLRC4-mimicry-induced cell death of 
necrosis-type cell lines (Fig. 2B), we next 
investigated whether the catalytic activity of 
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caspase-1 is involved in ASC-mediated necrosis. 
When SK-Mel-28 (SKC12N2) cells expressing 
C12N2 were treated with MDP, a fragment 
(p20) of mature caspase-1 was detected in the 
cell lysate and culture supernatant (Fig. 6A). 
Treatment with 40 µM Ac-YVAD-CMK 
completely inhibited the caspase-1 processing, 
but did not inhibit the ASC-mediated necrosis 
of SKC12N2 cells (Fig. 6B), supporting the 
notion that the caspase-1 catalytic activity is not 
required for ASC-mediated necrosis. To further 
confirm this notion, wild-type caspase-1, the 
catalytically inactive caspase-1-C285S mutant, 
or GFP was transduced into NUC12N2 cells 
using a lentiviral vector. The exogenous 
caspase-1 expression levels were comparable to 
those of endogenous caspase-1 in COLO205 
and SK-Mel-28 cells (Fig. 6C and see 
supplemental Fig. S6A). Both the wild-type and 
C285S mutant of caspase-1 converted the mode 
of NLRC4-mimicry-induced cell death from 
apoptosis to necrosis, but GFP did not (Fig. 6D 
and see supplemental Fig. S6B). These cells 
were further transfected with an expression 
plasmid for proIL-1β, and then stimulated with 
MDP. Importantly, cells expressing the 
wild-type, but not the mutant caspase-1, 
secreted IL-1β (Fig. 6E), confirming that the 
C285S mutant was catalytically inactive. These 
results indicate that the catalytic activity of 
caspase-1 is not required for ASC-mediated 
necrosis. 
 
Caspase-1, but not its catalytic activity, is 
essential for the ASC-mediated necrosis of S. 
aureus-infected monocytes. S. aureus 
α-haemolysin induces NLRP3- and 
ASC-dependent pyronecrosis in THP-1 cells 
(31). This necrotic cell death was reported to be 
caspase-1-independent, because it was not 
inhibited by Z-VAD-FMK. Therefore, we next 
investigated the role of caspase-1 and its 
catalytic activity in the S. aureus-induced death 
of NOMO-1 cells. Consistent with the previous 
report (31), the S. aureus-induced cell death 
exhibited a necrotic morphology (Fig. 7A), and 
this necrosis was inhibited by siRNAs for ASC 
and NLRP3 but not for NLRC4 (Fig. 7B). 
Similar to NLRC4-mimicry-induced necrosis, 
the S. aureus-induced necrosis was inhibited by 
CA-074Me, but not by Z-IETD-FMK (Fig. 7C). 
In addition, a caspase-3 inhibitor, 
Z-DEVD-FMK did not inhibit the S. 
aureus-induced necrosis, indicating that 
caspase-3, the executioner of apoptosis, was not 
involved in this cell death (Fig. 7C). 
Furthermore, Ac-YVAD-CMK that was 
sufficient to inhibit IL-1β production did not 
inhibit the S. aureus-induced necrosis (Fig. 7D). 
Similar results were obtained using THP-1 cells 
(see supplemental Fig. S7). Nonetheless, the S. 
aureus-induced necrosis was suppressed by 
caspase-1 knockdown (Fig. 7E). These results 
indicate that the S. aureus-induced necrosis 
requires caspase-1 but not its catalytic activity. 
Consistent with our observations in 
NLRC4-mimicry-induced necrosis, a short 
period of caspase-1 knockdown inhibited the S. 
aureus-induced IL-1β production but not 
necrosis, while longer knockdown suppressed 
both responses (Fig. 7F). However, S. 
aureus-induced necrosis was not inhibited even 
after 7 or 12-day exposure of NOMO-1 cells to 
Ac-YVAD-CMK (see supplemental Fig. S8), 
supporting further that the catalytic activity of 
caspase-1 is not required for the ASC-mediated 
necrosis. 
 
Caspase-1, but not its catalytic activity, is 
required for the NLRC4-dependent, ASC- 
independent necrosis of P. aeruginosa-infected 
monocytes. It was reported that P. aeruginosa 
infection induces NLRC4- and caspase-1- 
dependent pyroptosis in macrophages (32). 
Consistent with the report, we observed that P. 
aeruginosa induced necrosis in NOMO-1 cells 
(Fig. 7G), and this necrosis was inhibited by 
NLRC4-targeting siRNA but not by ASC- or 
NLRP3-targeting siRNA (Fig. 7H), although the 
necrosis observed after P. aeruginosa infection 
at a low multiplicity of infection (moi) was 
strongly suppressed by both NLRC4- targeting 
and ASC-targeting siRNAs (data not shown). 
Consistent with the above S. aureus infection 
model, the P. aeruginosa-induced necrosis was 
suppressed in NOMO-1 cells carrying the 
caspase-1-targeting shRNA (Fig. 7I). However, 
Ac-YVAD-CMK that was sufficient to inhibit 
IL-1β production did not inhibit the P. 
aeruginosa-induced necrosis (Fig. 7J). Thus, the 
caspase-1 catalytic activity is also dispensable 




In this study, we discovered that activation of 
ASC induces necrosis when cells express 
caspase-1, otherwise the same induces apoptosis. 
Thus, caspase-1 is a novel molecular 
determinant of cell death modes. Intriguingly, 
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we found that ASC-mediated necrosis does 
require caspase-1 expression, but not its 
catalytic activity. This conclusion was 
confirmed by experiments using a caspase-1 
inhibitor and a catalytically inactive caspase-1 
mutant. This is the first report of a catalytic 
activity-independent function of caspase-1. A 
caveat is that our results do not exclude the 
possibility that there are caspase-1 catalytic 
activity-dependent mechanisms of pyroptosis in 
addition to the catalytic activity-independent 
one. This concern is analogous to the fact that 
caspase-dependent DNase, which causes DNA 
degradation during apoptosis and hence would 
cause cell death, is not essential for the cell 
death itself (33). 
In contrast to our conclusion described above, 
it has been thought that pyroptosis of human 
monocytes requires caspase-1 catalytic activity. 
This conclusion has been drawn from 
experiments using high concentrations (50-200 
µM) of Z-VAD-FMK or Ac-YVAD-CMK (11, 
34). Such high concentrations of these inhibitors 
could non-specifically inhibit other proteases 
including cathepsin B (35). Thus, the 
requirement of caspase-1 catalytic activity in 
pyroptosis of human macrophages should be 
re-evaluated using a lower dose of 
Ac-YVAD-CMK. Recently, Broz et al 
demonstrated that autoproteolysis of caspase-1 
is required for IL-1β processing but not for 
pyroptosis of mouse macrophages infected by 
Salmonella or Legionella, although the 
proteolytic activity of caspase-1 was required 
for both responses (36). In addition, they 
demonstrated that formation of a large focus of 
ASC was required for IL-1β production, 
whereas formation of NLRC4-caspase1 
complexs was sufficient and ASC was not 
required for the cell death. Broz’s and our 
results are similar in that both indicate that the 
use of caspase-1 in IL-1β processing and cell 
death is somewhat different. However, they 
were different from each other in the 
requirement of the proteolytic activity of 
caspase-1 for cell death. This difference may be 
species difference. Actually, our preliminary 
experiments using mouse peritoneal 
macrophages showed that low concentrations 
(2-10 µM) of Ac-YVAD-CMK significantly 
inhibited Salmonella typhimurium- and P. 
aeruginosa-induced cell death, albeit less 
efficiently than it inhibited IL-1β release under 
the same conditions (see supplemental Fig. S9). 
In Broz’s experimental system, macrophages 
were killed in an ASC-independent manner. In 
contrast, we mainly investigated 
ASC-dependent necrosis in this study. However, 
the difference in ASC-dependency is unlikely to 
be a reason for the different requirement in 
terms of the caspase-1 proteolytic activity for 
necrosis, because ASC-independent necrosis of 
P. aeruginosa-infected NOMO-1 cells was not 
inhibited by Ac-YVAD-CMK (Fig. 7J). 
On the other hand, pyronecrosis has been 
mainly characterized using THP-1 cells infected 
with Shigella flexneri, Neisseria gonorrhoeae or 
adenovirus, or treated with S. aureus 
α-haemolysin (14,31,37,38). Pyronecrosis has 
been concluded to be caspase-1-independent, 
mainly because these cases of cell death were 
not inhibited by Z-VAD-FMK or 
Ac-YVAD-CMK at relatively low 
concentrations sufficient to inhibit 
caspase-1-mediated IL-1β secretion. Whether 
macrophages from caspase-1-deficient mice are 
resistant to Shigella-induced cell death has been 
controversial (14,39). In other experimental 
systems of pyronecrosis, the requirement for 
caspase-1 expression has not been examined. 
Thus, the requirement for caspase-1 in the 
pyronecrosis observed in the above 
experimental systems needs to be re-examined.  
Both pyroptosis and pyronecrosis are 
mediated by NLRs and ASC, and are 
accompanied by IL-1β production. 
Morphologically, both modes of cell death are 
characterized by rapid cell swelling followed by 
plasma-membrane rupture. Nuclear shrinkage 
has been observed for pyroptosis. However, it 
has not been clearly described whether 
pyronecrosis is also accompanied by nuclear 
shrinkage. Therefore, one cannot distinguish 
pyroptosis and pyronecrosis solely by the 
morphology of the dying cells. We observed 
nuclear shrinkage in some cells undergoing 
ASC-mediated necrosis. We found that all the 
instances of ASC-mediated necrosis examined 
in our study were inhibited by CA-074Me. This 
is a characteristic of pyronecrosis. However, it 
was recently reported that pyroptosis is also 
inhibited by CA-074Me (40). The sole factor 
that clearly discriminated the two modes of cell 
death was that caspase-1 was essential for 
pyroptosis, but not pyronecrosis. However, this 
distinction is now questionable as described 
above. Based on our results presented here, it is 
likely that pyroptosis and pyronecrosis are the 
same mode of cell death. The molecular 
mechanisms of pyroptosis and pyronecrosis 
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have not been well understood. Our finding that 
caspase-1 is capable of inducing necrosis 
independently of its catalytic activity may 
provide important insight into the molecular 
mechanism of these necrotic cell death modes. 
ASC-mediated necrosis induced by 
NLRC4-mimicry in CLC12N2 cells and by the 
NLRP3-Y570C mutant in NOMO-1 cells was 
converted to apoptosis when caspase-1 
expression was suppressed by RNA interference. 
However, the ASC-mediated necrosis induced 
by S-aureus infection in NOMO-1 cells was 
merely suppressed, not converted to apoptosis, 
by reduced caspase-1 expression. One possible 
explanation for these distinctive outcomes by 
different stimuli in the same cell line is that the 
host cells or microbes in S. aureus-infected 
NOMO-1 cells might produce something that 
inhibits caspase-8 activation. Further study is 
required to clarify this point. 
Although CA-074Me, the well-known 
cathepsin B inhibitor abrogated ASC-mediated 
necrosis, there was no correlation between 
cathepsin B expression and the mode of 
ASC-mediated cell death (see supplemental Fig, 
S10A). It should be note that whether cathepsin 
B plays an essential role in this type of cell 
death is not clear, because we previously found 
that knockdown of cathepsin B expression using 
siRNA failed to inhibit the MDP-induced cell 
death of CLC12N2 cells (18). Consistently, 
knockdown of cathepsin B in NOMO1-C12N2 
cells also failed to inhibit the MDP-induced cell 
death (see supplemental Fig. S10B). Thus, 
further experiments are required to determine 
the target of CA-074Me in the inhibition of 
ASC-mediated necrosis. 
Here, we found that a short-term knockdown 
of caspase-1 abrogated IL-1β production but not 
ASC-mediated necrosis, whereas its long-term 
knockdown diminished both responses. Thus, 
the caspase-1 involved in necrosis might have a 
longer half-life compared to that involved in 
IL-1β secretion. Alternatively, the absence of 
caspase-1 might result in gradual decrease of 
the amount and/or activity of another molecule 
that was essential for the ASC-mediated 
necrosis. Further study aiming to explain this 
interesting phenomenon may provide a clue to 
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FIGURE 1. ASC activation induces apoptosis or necrosis in various tumor cell lines. A, ASC and β-actin levels 
were examined by Western blotting. B-E, The indicated cell lines were transduced with a lentiviral vector 
expressing C12N2. The cells were then treated with or without MDP (100 ng/ml). B, Cell morphology was 
examined under a microscope. Representative necrotic and apoptotic cells are shown by arrows and arrowheads, 
respectively. Scale bars, 20 µm. C, Leukemia and melanoma cell lines were stained with propidium iodide (PI) 
and Cy5-annexin V, and the percentages of apoptotic and necrotic cells were determined by flow cytometry. 
The staining profiles are shown in supplemental Fig. S1. D, Pancreatic cancer cell lines were stained with 
Hoechst33342 and PI, and examined under a fluorescence microscope. Necrotic cells (arrows) had 
morphologically normal nuclei that were stained with PI. Scale bar in the top left panel, 20 µm. E, Apoptotic 
and necrotic cells were counted under a fluorescence microscope. At least 500 total cells were counted for each 
group. Error bars in C and E indicate S.D. 
 
FIGURE 2. Effect of protease inhibitors on ASC-mediated cell death. A, NUGC-4, HMV-II, and G-361 cells 
expressing C12N2 were left untreated or were treated with 40 µM of  Z-IETD-FMK or CA-074Me for 1 h, and 
were then cultured with or without MDP (100 ng/ml) for 12 h. The proportion of apoptotic cells was determined 
as described in Fig. 1C. B, COLO205, THP-1, NOMO-1, and SK-Mel-28 cells expressing C12N2 were 
pre-treated with the indicated inhibitors (20, 40 and 80 µM) for 1 h, and then cultured with or without MDP 
(100 ng/ml) for 8 h. Cell viability was assessed by WST-1 assay. Cell Death (%) = {(A450 of cell culture without 
MDP - A450 of cell culture with MDP) / A450 of cells cultured without MDP} x 100. Error bars in A and B 
indicate S.D. 
 
FIGURE 3. The RIP1-RIP3 axis is not involved in ASC-mediated necrosis. A, The RIP3 (RIPK3) and β-actin 
(ACTB) mRNA levels in the indicated tumor cell lines were analyzed by RT-PCR. B, THP-1 cells (left) or 
C12N2-expressing THP-1 cells (right) were pre-treated with necrostatin-1 (10 µM) for 1 h. Then, the THP-1 
cells were treated with recombinant mouse TNF-α (30 ng/ml) and Z-VAD-FMK (40 µM) for 48 h, while the 
C12N2-expressing THP-1 cells were treated with MDP (100 ng/ml) for 10 h. Cell viability was assessed by 
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WST-1 assay as described in Fig. 2B. Error bars indicate S.D. 
 
 
FIGURE 4. Caspase-1 expression correlates with the necrotic phenotype. A, CLC12N2-Apo and CLC12N2-Nec 
cells were treated with MDP (100 ng/ml) for 12 h, then analyzed as described in Fig. 1B. B, CLC12N2-Apo and 
CLC12N2-Nec cells were pre-treated with Z-IETD-FMK (5, 10, 20, or 40 µM) for 1 h or left untreated, and 
then were treated with MDP (100 ng/ml) for 12 h. The percentages of apoptotic and necrotic cells were 
determined by flow cytometry. C, Gene expression profiles of CLC12N2-Nec and CLC12N2-Apo cells or 
COLO205 and NUGC-4 cells were compared by DNA-microarray analyses. The top 10 genes with greater 
expression in CLC212N2-Nec cells than in CLC12N2-Apo cells are listed in the upper panel, while those 
expressed more in CLC12N2-Apo cells than in CLC12N2-Nec cells are shown in the lower panel. Numbers 
shown are the fold difference in gene expression levels between the indicated cell lines. Original datasets of the 
microarray analyses are available at CIBEX (http://cibex.nig.ac.jp/index.jsp, accession no. CBX131). D, The 
caspase-1 mRNA levels relative to that of β-actin, as determined by quantitative RT-PCR, are shown for the 
indicated cell lines. E, Caspase-1 and β-actin protein levels in the indicated cells were examined by Western 
blotting. Error bars in B and D indicate S.D. 
 
FIGURE 5. Caspase-1 with a long half-life is required for ASC-mediated necrosis. A, CLC12N2-Nec cells were 
transfected with control (siCont, circles) or caspase-1-targeting siRNA (siCasp1, triangles) 1–3 times at 3-day 
intervals. At 3, 6, or 9 days after the first transfection, the cells were treated with MDP (100 ng/ml) for 12 h, and 
the proportions of apoptotic (open symbols) and necrotic cells (closed symbols) were determined by flow 
cytometry as described in Fig. 1B. Caspase-1 (Casp1) and GAPDH expression levels at the indicated times 
before MDP stimulation were examined by Western blotting (lower panels). B, NUC12N2 and NU-GFP-Casp1 
cells were treated with MDP (1000 ng/ml) or left untreated for 6 h, then stained with Hoechst33342 and PI, and 
examined under a fluorescence microscope. The upper and lower panels show Hoechst- and PI-stained images, 
respectively. Apoptotic cells had pyknotic nuclei that were brightly stained with Hoechst33342 but not with PI, 
while necrotic cells had morphologically normal nuclei that were stained with PI. Scale bar, 20 µm. 
GFP-caspase-1 (GFP-Casp1) and GAPDH expression levels in these cells before MDP stimulation were 
examined by Western blotting (lower panels). C, NOMO-1 cells treated with control or ASC-targeting siRNA 
(siASC) for 72 h were transduced with empty lentiviral vector (Vector), or with the vector expressing wild-type 
(wt) NLRP3 or its Y570C mutant (mt). Twelve hours after transduction, cytotoxicity was assessed by LDH 
release (upper panel). ASC and GAPDH expression levels were examined by Western blotting 48 h after the 
siRNA transfection (lower panels). D and E, NOMO1-shCont and NOMO1-shCasp1 cells were transduced with 
an empty lentiviral vector or one expressing the wild-type or Y570C mutant of NLRP3, and were cultured for 
12 h. D, Cytotoxicity was assessed as described in (C). Caspase-1 and GAPDH levels were examined by 
Western blotting (lower panels). E, Cells were examined as described in (B). Scale bar, 20 µm. Arrowheads 
indicate apoptotic cells. F, NOMO1-shCont and NOMO1-shCasp1 cells were pre-treated with Z-IETD-FMK 
(40 µM) or DMSO (solvent control) for 1 h. Cells were then transduced with a lentiviral vector expressing the 
Y570C mutant of NLRP3, and were further cultured for 12 h. Apoptotic and necrotic cells were counted under a 
fluorescence microscope. Error bars in A, C, D and F indicate S.D. 
 
FIGURE 6. Caspase-1 catalytic activity is not required for ASC-mediated necrosis. A, SK-Mel-28 cells stably 
expressing C12N2 (SKC12N2) were treated with MDP (1000 ng/ml) for the indicated period. The large subunit 
of mature caspase-1 (p20) in cell lysates and culture supernatants was detected by Western blotting. B, 
SKC12N2 cells were left untreated or were pre-treated with Ac-YVAD-CMK (40 µM), and then stimulated 
with MDP (1000 ng/ml) for 4 h. Cytotoxicity was assessed by an LDH release assay, and caspase-1 p20 in 
culture supernatants was detected by Western blotting. C and D, NUC12N2 cells were transduced with a 
lentiviral vector expressing GFP, wild-type caspase-1 or the C285S mutant of caspase-1. C, Caspase-1 and 
β-actin levels in the indicated cells were examined by Western blotting. D, NUC12N2 cells expressing GFP, 
wild-type caspase-1 (WT) or the C285S mutant of caspase-1 (CS) were cultured with MDP (1000 ng/ml) for 6 h, 
and then stained with Hoechst33342 and PI. Apoptotic and necrotic cells were counted under a fluorescence 
microscope. E, The cells described in (D) were further transfected with a pro-IL-1β-expressing plasmid. After 
21 h, the cells were treated with MDP (1000 ng/ml) for 3 h, and IL-1β in the culture supernatant was measured 
by ELISA. Error bars in B, D and E indicate S.D. 
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FIGURE 7. Caspase-1, but not its catalytic activity, is required for the necrotic cell death of monocytes infected 
with bacteria. A and G, Optical phase contrast images of NOMO-1 cells either uninfected (left panels), or 
infected with S. aureus (A, right panel) or P. aeruginosa (G, right panel) at an moi of 20 for 4 h. Scale bar, 20 
µm. B and H, NOMO-1 cells were transfected with control, ASC-, NLRP3-, or NLRC4-targeting siRNA. After 
72 h, the cells were infected with S. aureus (B, moi 20 or 50) for 2 h, or with P. aeruginosa (H, moi 50) for 4 h. 
The knockdown efficiency was examined by RT-PCR (B, right panels). C, NOMO-1 cells were pre-treated with 
20 µM of the indicated inhibitors for 1 h. Cells were then infected with S. aureus for 2 h. D and J, NOMO-1 
cells were pre-treated with the indicated concentrations of Ac-YVAD-CMK for 1 h. The cells were then 
infected with S. aureus (moi 20) for 2 h (D), or with P. aeruginosa (moi 50) for 4 h (J). E and I, 
NOMO1-shCont and NOMO1-shCasp1 cells were infected with S. aureus (moi 50) for 2 h (E), or P. aeruginosa 
(moi 50) for 4 h (I). F, NOMO-1 cells were transfected with control (Cont) or caspase-1-targeting siRNA (C1) 
1–3 times at 4-day intervals. At 4, 8, or 12 days after the first transfection, the cells were infected with S. aureus 
(moi 20) for 2 h. Caspase-1 and GAPDH levels at the end of a 4-, 8- or 12-day culture before infection were 
examined by Western blotting. B-F and H-J, Cytotoxicity was assessed by LDH release assays. The amount of 
IL-1β in culture supernatants was examined by ELISA. % of control = (value of cells treated with 
Ac-YVAD-CMK or caspase-1-targeting siRNA /value of cells treated with the solvent control or control 







































Video S1. CLC12N2-Nec cells were treated with MDP (100 ng/ml). Starting 3 h after the MDP addition, 
images were captured every 7.5 s for 25 min and are displayed at 500 frames/ min. 
 
Video S2. CLC12N2-Apo cells were treated with MDP (100 ng/ml). Starting 3 h after the MDP addition, 





FIGURE S1. ASC activation induces 
apoptosis or necrosis. A, Two-dimensional 
(propidium iodide and Cy5-annexin V) 
staining profiles of the cells described in 
Fig. 1C. B, Time course of the staining 
profiles of apoptosis-type cells after MDP 
addition. A and B, MDP-treated THP-1, 
NOMO-1, and SK-Mel-28 cells exhibited 
increased PI staining preceding or occurring 
simultaneously with increased Cy5- 
Annexin V staining. Therefore, the PI(+) 
Cy5-Annexin V(+) cells were considered 
necrotic cells. On the other hand, 
MDP-treated HMV-II and G-361 cells 
exhibited an increase in Cy5-Annexin V 
staining that preceded PI staining. Thus, the 
PI(+) Cy5-Annexin V(+) cells were 
considered apoptotic cells. The morphology 
of the dying cells (Fig. 1B) and the fact that 
pretreatment with Z-IETD-FMK inhibited 
the development of PI(+) Cy5-Annexin 
V(+) cells from the latter cell lines but not 







FIGURE S2. The mRNA expression levels in apoptosis-type and necrosis-type cell lines of the genes listed in 
the upper panel of Fig. 1C. The mRNA levels of the indicated genes were analyzed by real-time PCR. Relative 
mRNA expression levels normalized to that of ACTB (β-Actin) are shown. The primer sequences are shown in 
supplementary Table S1. FZD10, frizzled homolog 10; SPINK1, serine peptidase inhibitor, Kazal type 1; CALB1, 
calbindin 1; DPEP1, dipeptidase 1; CARD16, caspase recruitment domain family, member 16 (also known as 
COP1); CARD17, caspase recruitment domain family, member 17 (also known as INCA); CTSS, cathepsin S; 




FIGURE S3. CARD16 knockdown in CLC12N2-Nec cells does not convert the cell death mode. 
CLC12N2-Nec cells were transfected with control, caspase-1-targeting, or CARD16-targeting siRNA (Invitrogen, 
HSS174333) on days 0, 3, and 6. On day 9, the cells were treated with MDP (100 ng/ml) for 12 h, and the 
proportions of apoptotic and necrotic cells were determined by flow cytometry as described in Fig. 1B. The 
expression levels of CARD16 and ACTB (β-actin) on day 8 were examined by RT-PCR (lower panels). The 
following primers were used for PCR: CARD16, 5’-GCCATGGCCGACAAGGT-3’ and 





FIGURE S4. The mRNA expression levels in apoptosis-type and necrosis-type cell lines of the genes listed in 
the lower panel of Fig. 1C. The mRNA levels of the indicated genes were analyzed by real-time PCR. Relative 
mRNA expression levels normalized to that of ACTB (β-Actin) are shown. The primer sequences are shown in 
supplementary Table S1. SERPINE2, serpin peptidase inhibitor, clade E, member 2; GPSM1, G-protein signaling 
modulator 1; HOMER3, homer homolog 3; MIA, melanoma inhibitory activity; CCNG2, cyclin G2; NCS1, 
neuronal calcium sensor 1; ARHGEF26, Rho guanine nucleotide exchange factor 26; SMARCA1, SWI/SNF related, 
matrix associated, actin dependent regulator of chromatin, subfamily a, member 1; AQP5, aquaporin 5; SRPX2, 




FIGURE S5. Apoptosis-type cells do not express caspase-1. 
RT-PCR was used to examine caspase-1 and β-actin mRNA 
expression in four human cancer cell lines (A549, HCT116, 
SW480, MKN45) that exhibit apoptosis in response to ASC 






FIGURE S6. The catalytic activity of 
caspase-1 is not required for 
ASC-mediated necrosis. A, Total RNA was 
isolated from the indicated cell lines, and the 
mRNA levels of endogenous and exogenous 
caspse-1 and β-actin were detected by 
RT-PCR. B, NU-GFP, NU-Casp1WT, and 
NU-Casp1C285S cells were cultured with 
MDP (1000 ng/ml) for 6 h. Cytotoxicity was 






FIGURE S7. Ac-YVAD-CMK inhibits 
the IL-1β release but not the necrosis 
induced by bacterial infection in 
THP-1 cells. A, THP-1 cells were 
treated with PMA (10 ng/ml) for 12 h to 
allow cells to adhere to the culture 
plate, and the cells were then infected 
with FITC-labeled S. aureus (moi 50) in 
the presence of 
4',6-diamidino-2-phenylindole (DAPI). 
Time-lapse images were recorded every 
3 min beginning 3 h after infection. 
Scale bar, 20 µm. Nuclear staining with 
DAPI and the swelling of S. 
aureus-infected cells indicates that S. 
aureus induced necrosis in THP-1 cells. 
B, THP-1 cells were pretreated with 
Ac-YVAD-CMK (10 µM) for 1 h, and 
then infected with S. aureus for 2 h or 
with P. aeruginosa for 4 h. The culture 
supernatants were examined for LDH 




FIGURE S8. Long-term inhibition of caspase-1 activity does not 
supress S. aureus-induced necrosis of NOMO-1 cells. NOMO-1 
cells were treated with Ac-YVAD-CMK for 7 or 12 days. Cells 
were then infected with S. aureus at the indicated moi in the 
presence of Ac-YVAD-CMK for 4 h. Cytotoxicity was assessed by 





FIGURE S9. Caspase-1 catalytic activity seems 
to be required for pyroptosis of mouse 
macrophages. A, Thioglycollate-induced 
peritoneal macrophages were prepared from 
wild-type (WT, Caspase-1+/+) or ICE KO 
(Caspase-1–/–) mice. The macrophages were 
primed with LPS (100 ng/ml) for 12 h, and then 
infected with Salmonella (S.) typhimurium 
(ATCC 14028s) or P. aeruginosa for 2 h. B, 
Thioglycollate-induced peritoneal macrophages 
from wild-type mice were primed with LPS (100 
ng/ml) for 4 h. The LPS-primed macrophages 
were pre-treated with the indicated concentrations 
of Ac-YVAD-CMK for 1 h, and then infected 
with S. typhimurium or P. aeruginosa for 1 h. 
LDH release and IL-1β production were analyzed 






FIGURE S10. Cathepsin B may not be the target of CA-074Me in the inhibition of ASC-mediated necrosis. A, 
Total RNA was extracted from the indicated cell lines, and the expression of cathepsin B mRNA (CTSB) was 
examined by RT-PCR analysis. B, NOMO1-C12N2 cells were transfected with 20 nM of a control siRNA, a pool of 
four CTSB siRNAs (Dharmacon, L-004266-00), or three individual CTSB siRNAs (invitrogen, HSS102475-7). 
Forty eight hours later, cells were treated with MDP (300 ng/ml) for 6 h. Cell death was assessed by WST-1 assays 




Table S1. The primer sequences1) used in Fig. S2 and S4. 
 
Gene Sense Antisense 
FZD10 CGGTGAAGACCATCCTGATCC CAGCTTGTCCGTGTTCTCG 
CD244 AAGCCACACCCTGAATCTCAC CCAAAAACGGCCAAAATCTGAA 
SPINK1 AGTCTATCTGGTAACACTGGAGC ACACGCATTCATTGGGATAAGT 
CALB1 AGGGAATCAAAATGTGTGGGAAA TCCTTCAGTAAAGCATCCAGTTC 
DPEP1 AGAGCCCCGGTCATCTTCA CCTTGTTGGTGCAGGAAATGTA 
CARD16 TGCAGAGGTGCCATGTTCAG TTTATGCAAGGGGAGCAGCAGAAG 
CARD17 AATGGCTTACTGGGTGAATTATTGG TGTGATGCAAATTTGGCATGCTGGA 
CTSS ATGAAACGGCTGGTTTGTGTG TGCTCCAGGTTGTGAAGCATC 
BTNL3 GGGGCGTGTCTCTCTAAGG CGTCAACATATCCCACGATGGA 
SERPINE2 ACGCCGTGTTTGTTAAGAATGC CGTTGACGAGGACCAGTCT 
GPSM1 GGAGCCGGGCCTATCTCTAAA CTCTTGCTGCCAGTAAGCATC 
HOMER3 GGCGAGGAAAAACTGTTCCG ACAACATCTTCTTTAGCCGCTC 
MIA GTCAGGGGTGGTCCTATGC GGTCAGGAATCGGCAGTCG 
CCNG2 TGCCTAGCCGAGTATTCTTCT TGTTTGTGCCACTTTGAAGTTG 
NCS1 TTCAAGCTCTACGACTTGGACA GCTCCACGGTATTCCCCAC 
ARHGEF26 CCGTGGTTTTGAGTACAAACAGC CGCACCTTGAGGAGTCTCTTG 
SMARCA1 GATGCGACCGCCACTATCG AGATTTAGGCGCTTTAGCAGC 
AQP5 CTGTCCATTGGCCTGTCTGTC GGCTCATACGTGCCTTTGATG 
SRPX2 GATGAGATGCCACGCACTACC TCTTCCATGCAGATTCGGCTG 
 
1) These primer sequences, with the exception of those for CARD16 and CARD17, were obtained from 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/). 
 
